WEKO3
アイテム
Carbon ion therapy at NIRS
https://repo.qst.go.jp/records/62682
https://repo.qst.go.jp/records/626824eeceb16-0f5c-4cbc-b9d6-f615f4eddb19
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2008-08-19 | |||||
| タイトル | ||||||
| タイトル | Carbon ion therapy at NIRS | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Mizoe, Junetsu
× Mizoe, Junetsu× Tsujii, Hirohiko× 溝江 純悦× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | High LET charged particle therapy with carbon ions has been of interest in the treatment of malignant tumors because of better dose localization in the tumor volume and greater biologic effectiveness. Between June 1994 and August 2007, a total of 3,452 patients were treated by carbon ion radiotherapy at NIRS. They consisted of 564 patients with prostate cancer, 488 patients with non small cell lung cancer (NSCLC), 432 patients with head and neck cancer (H&N), 374 patients with bone and soft tissue (B&S) sarcomas and so on. They also consisted of 1,561 patients of phase I/II dose escalation study and 1,891 patients of phase II clinical study. For the patients with prostate, H&N and B&S sarcomas, the results of phase II study with the dose fractionation methods of 16~20 fractions through 4~5 weeks showed good local control and acceptable late normal tissue morbidity. For the patients with hepatic cell carcinoma, phase II study by two fractions is ongoing. For the patients with NSCLC, phase I/II dose escalation study of one day fraction is undergoing. The results of phase II clinical studies and preliminary results of phase I/II studies showed acceptable normal tissue reactions and good local control of the irradiated sites. In mucosal malignant melanoma of the H&N, the phase II study had achieved a satisfactory local control rate (75% at 5 years), but the survival rate was not commensurate (36% at 5 years) with this favorable local control rate. In view of this, a new protocol was commenced for the purpose of verifying the validity of preventive chemotherapy against distant metastasis, the major cause of death in this malignancy. As a preliminary result of this combined therapy, the five-year local control rate was 87% and the five-year overall survival rate was 48%. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | CAARI 2008 20th International Conference on the Application of Accelerators in Research and Industry | |||||
| 発表年月日 | ||||||
| 日付 | 2008-08-15 | |||||
| 日付タイプ | Issued | |||||
